Randomized, double-blind, placebo-controlled, crossover trial of oral doxycycline for epistaxis in hereditary hemorrhagic telangiectasia

BACKGROUND: Vascular malformations in hereditary hemorrhagic telangiectasia (HHT) lead to chronic recurrent bleeding, hemorrhage, stroke, heart failure, and liver disease. There is great interest in identifying novel therapies for epistaxis in HHT given its associated morbidity and impact on quality...

Descripción completa

Detalles Bibliográficos
Autores principales: Thompson, K. P., Sykes, J., Chandakkar, P., Marambaud, P., Vozoris, N. T., Marchuk, D. A., Faughnan, M. E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9640829/
https://www.ncbi.nlm.nih.gov/pubmed/36344987
http://dx.doi.org/10.1186/s13023-022-02539-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9640829/
https://www.ncbi.nlm.nih.gov/pubmed/36344987
http://dx.doi.org/10.1186/s13023-022-02539-8

Ejemplares similares